Concepedia

Gregory Friberg

GF

Statistics

Publications

20

Citations

4.8K

H-Index

19

Active since

2004

Affiliations

Amgen (United States)(Current)

University of Chicago

Princess Margaret Cancer Centre

The University of Texas MD Anderson Cancer Center

Duke Medical Center

Gregory Friberg is an author at Amgen (United States) specializing in medicine, oncology, and pharmacology.

Publications per year

2004–2021

20

Publications

20

Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation

Ferdinandos Skoulidis, Bob T. Li, Grace K. Dy et al. · New England Journal of Medicine · 2021 · 1.8K citations · Full text

, , +17

KRAS <sup>G12C</sup> Inhibition with Sotorasib in Advanced Solid Tumors

David S. Hong, Marwan Fakih, John H. Strickler et al. · New England Journal of Medicine · 2020 · 1.7K citations · Full text

, , +1

Phase II Trial of Bevacizumab Plus Gemcitabine in Patients With Advanced Pancreatic Cancer

Hedy L. Kindler, Gregory Friberg, D. A. Singh et al. · Journal of Clinical Oncology · 2005 · 458 citations · Full text

, , +17

Phase II Study of Ganitumab, a Fully Human Anti–Type-1 Insulin-Like Growth Factor Receptor Antibody, in Patients With Metastatic Ewing Family Tumors or Desmoplastic Small Round Cell Tumors

William D. Tap, George D. Demetri, Phillip Barnette et al. · Journal of Clinical Oncology · 2012 · 219 citations

, , +17

Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: A trial of the Chicago, PMH, and California Phase II consortia

Halla Nimeiri, Amit M. Oza, Robert J. Morgan et al. · Gynecologic Oncology · 2008 · 151 citations · Full text

, , +11

1–5 of 20